The official account for @Novartis News & Media Updates. For media inquiries: [email protected]. See our community guidelines: https://t.co/YalUIWxirZnovartis.com/news Basel, SwitzerlandJoined December 2018
New data at @EAACI_HQ highlight potential for first targeted therapy in chronic inducible urticaria (CIndU), addressing a significant unmet need for patients living with this condition. novartis.social/6013v9LL9#EAACI_HQ#NovartisNews
Novartis will present data from 10 abstracts at @EAACI_HQ starting June 12, spanning clinical trial results and real-world evidence on chronic urticaria patient burden and treatment experience. novartis.social/6010v5yN6#EAACI_HQ#NovartisNews
#News#Novartis announces at 2026 ASCO® Annual Meeting that CML treatment continued to show superior efficacy and a favorable safety and tolerability profile at week 144 in newly diagnosed CML #ASCO26novartis.social/6019vbGkh
#News: Novartis will present late-stage and long-term data at #ERA2026 that advance scientific understanding of kidney disease and reinforce portfolio strength. novartis.social/6013vXFdx
#News: Novartis shares new data at #ASCO26 and #EHA26 highlighting RLT innovation and reinforcing leadership in prostate cancer, breast cancer and hematology.
go.novartis.social/4dsltfC
#News: Learn about our new RLT manufacturing site in Denton, Texas, USA. A critical part of our $23 billion US investment in research and manufacturing, this milestone helps bring highly personalized cancer therapies closer to patients: 🔗novartis.social/6013vM0f1
#News: Learn about our new facility plan for Morrisville, North Carolina, USA. A site for active pharmaceutical ingredient (API) manufacturing, it’s a critical part of our $23 billion US investment that we announced one year ago today: novartis.social/6010vyZBs
#NVSQ126 Novartis social media posts on Q1 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information.
#NVSQ126 Novartis social media posts on Q1 2026 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis.
$NVS $NOVN #NovartisNews
The European Commission has approved the first oral targeted treatment for chronic spontaneous urticaria. Clinical studies showed symptom improvements as early as Week 1, a favorable safety profile. novartis.social/6019vGGuP#Dermatology#Immunology#NovartisNews
#News: Today’s FDA approval of a treatment for pediatric patients age 12+ with moderate to severe #HidradenitisSuppurativa (#HS) marks a major step forward for this patient population.
Learn more about how Novartis is pioneering change in Immunology: novartis.social/6019QlCwv
Novartis announces positive CHMP opinion in chronic spontaneous urticaria (CSU), with improvements observed as early as Week 1 in Phase III studies and a favorable safety profile. A potential first targeted oral option for CSU in Europe. novartis.social/6016QbsXE#Dermatology#Immunology#NovartisNews
New findings at #ASCOGU26 from our real-world evidence platform for metastatic prostate cancer answer critical questions on treatment sequencing and patient outcomes – supporting clinicians as they navigate patient care.
👉 Learn more: novartis.social/6010Qwhku#NovartisNews
128K Followers 799 FollowingBiotech reporter @statnews. Dog ❤️er. Polk Award winner. #COYS. Said one analyst: The likes of Adam Feuerstein attack viciously. On Signal: stataf.54
20K Followers 908 FollowingReimaginamos la medicina para mejorar y prolongar la vida de las personas | Nuestras normas de la comunidad: https://t.co/HiQC66XFca
19K Followers 9K FollowingProfessor of Chemical Biology and Molecular Therapeutics at UC Berkeley; Departments of Chemistry and Molecular and Cell Biology; Co-Director of @MTI_UCB
544 Followers 8K FollowingPredestined. In exile. Sheep following The Good Shepherd. Intoxicated by His Love. Merrying in His Grace. Settled in His mercy. PharmaEvangelist.
1 Followers 51 FollowingWorking for better patient outcomes-Maximising value in precision oncology: PET CT | Theranostics | Precision medicine | See what you treat, treat what you see.
791 Followers 720 FollowingWaddling my way to financial freedom — one compound interest snowball at a time 🐧
Bullish Bitcoin/AI/Tech 🤑
Austrian Economics & Free Market Capitalism 📈
2K Followers 617 FollowingGlobal biopharma company developing radiopharmaceuticals to address unmet medical need in oncology and rare diseases. ASX: TLX | NASDAQ: TLX
422 Followers 3K FollowingScience/anime/politics freak. I tweet my thoughts in Español & English, not necessarily the views of my employer. RT not necessarily endorsement.
64 Followers 6K FollowingGraduate student studying Artificial Intelligence. Science Enthusiast. I like coding and ecology. I love the Creator. she/her.
20K Followers 908 FollowingReimaginamos la medicina para mejorar y prolongar la vida de las personas | Nuestras normas de la comunidad: https://t.co/HiQC66XFca
5K Followers 344 FollowingThe Friedrich Miescher Institute for Biomedical Research (FMI), affiliated with @UniBasel & @NovartisScience, conducts research at the forefront of biomedicine.
9K Followers 685 FollowingWe help cities tackle cardiovascular disease and advance health equity through data and AI.
See our community guidelines: https://t.co/ONPDqoeaHR
5K Followers 303 FollowingWe apply our expertise and full organizational capability to address major, unresolved global health challenges. Our community guidelines: https://t.co/uSPWMoXxpA
7K Followers 678 FollowingNovartis est un leader mondial dans l’offre de médicaments destinés à améliorer et prolonger la vie.
Charte éditoriale-mentions légales : https://t.co/OoDUBbBTvV
6K Followers 556 FollowingHealthcare news from the UK Novartis Group. We're discovering new ways to improve & extend people's lives. See our community guidelines: https://t.co/2ZbpPwQE7E